Vafseo Approved for Anemia Due to CKD in Patients on Dialysis
Vafseo is an oral reversible inhibitor of hypoxia-inducible factor (HIF)-prolyl-4-hydroxylases (PH)1, PH2, and PH3.
Source: renalandurologynews.com
Page 7 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Boxed Warning Today - Breaking & Trending Today
UPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING
/PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be participating in the 2024 American Academy of Neurology (AAN)...
Source: prnewswire.com
Marius Pharmaceuticals Announces Final Published Phase 3 Data from MRS-TU-2019EXT Studying the Safety and Efficacy of FDA-Approved KYZATREX® (testosterone undecanoate) CII Capsules
/PRNewswire/ -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced...
Source: prnewswire.com
FDA Expands Enhertu Indication to HER2-Positive Solid Tumors
The move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate.
Source: medscape.com
FDA Approves Enhertu for Some With HER2-Positive Solid Tumors
Enhertu has been approved by the FDA for certain patients with unresectable or metastatic HER2-positive solid tumors.
Source: curetoday.com